Back to Journals » ImmunoTargets and Therapy » Volume 4

Update on use of aldesleukin for treatment of high-risk metastatic melanoma

Authors Amaria R, Reuben A, Cooper Z, Wargo JA

Received 13 January 2015

Accepted for publication 25 February 2015

Published 7 April 2015 Volume 2015:4 Pages 79—89


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Editor who approved publication: Professor Michael Shurin

Rodabe N Amaria,1 Alexandre Reuben,2 Zachary A Cooper,2,3 Jennifer A Wargo2,3

1Department of Melanoma Medical Oncology, 2Department of Surgical Oncology, 3Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract: High-dose interleukin-2 has been used for the treatment of metastatic melanoma since 1998 based on data proving durable complete responses in up to 10% of treated patients. The immunomodulatory effects of this critical cytokine have been instrumental in the development of immunotherapy for melanoma and other cancers. However, with the advent of new therapies, its use as a front-line agent has come into question. Nonetheless, there is still a role for interleukin-2 as monotherapy, as well as in combination with other agents and in clinical trials. In this article, we review preclinical and clinical data regarding interleukin-2, its pharmacology and mechanism of action, its toxicity profile, and its use in ongoing and planned clinical trials. We also explore the future of this agent within the treatment landscape for melanoma.

Keywords: aldesleukin, melanoma, immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]